FDA指导原则:孕妇纳入临床试验的科学和伦理考虑(草案)

2019-10-04 美国食品和药品监督管理局 FDA

本指南根据食品和药物管理局(FDA 或机构)目前对此问题的看法,就如何以及何时将孕妇纳入药物和生物制品的药物开发临床试验提供了建议。 具体而言,该指南支持通过明智地将孕妇纳入临床试验并仔细关注潜在的胎

中文标题:

FDA指导原则:孕妇纳入临床试验的科学和伦理考虑(草案)

英文标题:

Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials

发布日期:

2019-10-04

简要介绍:

本指南根据食品和药物管理局(FDA 或机构)目前对此问题的看法,就如何以及何时将孕妇纳入药物和生物制品的药物开发临床试验提供了建议。 具体而言,该指南支持通过明智地将孕妇纳入临床试验并仔细关注潜在的胎儿风险,以知情和平衡的方法收集妊娠期间药物和生物制品使用的数据。 本指南草案旨在作为各实体之间持续讨论的焦点,例如 FDA、制药商、学术界、机构审查委员会 (IRB) 和参与孕妇临床试验的其他机构。

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067519, encodeId=e3ca106e519a6, content=FDA厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:52 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067518, encodeId=c831106e518b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:45 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063037, encodeId=d4eb106303e2a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=231c5644126, createdName=ms9000001509650266, createdTime=Fri Oct 22 22:00:06 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-11-06 1e1ac4a1m23(暂无匿称)

    FDA厉害

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067519, encodeId=e3ca106e519a6, content=FDA厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:52 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067518, encodeId=c831106e518b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:45 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063037, encodeId=d4eb106303e2a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=231c5644126, createdName=ms9000001509650266, createdTime=Fri Oct 22 22:00:06 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-11-06 1e1ac4a1m23(暂无匿称)

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067519, encodeId=e3ca106e519a6, content=FDA厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:52 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067518, encodeId=c831106e518b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Sat Nov 06 10:57:45 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063037, encodeId=d4eb106303e2a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=231c5644126, createdName=ms9000001509650266, createdTime=Fri Oct 22 22:00:06 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-22 ms9000001509650266

    学习了

    0